. He can be reached at nsaraceno@mjhlifesciences.com.

Videos

In the final part of his Pharma Commerce video interview, Colin Banas, MD, DrFirst’s chief medical officer, explains how amid soaring patient and provider frustration, new HTI-4 standards are rapidly forcing change across the insurance and technology sectors to solve the current "transparency problem," making the status of a life-saving prescription as clear and actionable as tracking a takeout order.

HTI-4 Standards Target Lack of Transparency in Medication Access

Podcasts

In today’s Pharma Pulse, new trials confirm AI chatbots are a successful and sustainable tool for increasing pneumococcal vaccine uptake among older adults and much more.

Pharma Pulse: Lilly’s Jaypirca Challenges Imbruvica, as AI Chatbots Could Prove Key to Boosting Vaccine Rates

In the second part of his Pharma Commerce video interview, Colin Banas, MD, DrFirst’s chief medical officer, points out that while real-time benefit tools are improving coverage visibility at the point of care, true efficiency requires actionable insights and standardized ePA, an area still “laying the tracks.”

Price Transparency Advances, Prior Authorization Still Stalls

Articles

Artificial intelligence is fundamentally transforming medical affairs from a reactive function into a strategic partner by converting disparate data into "precision medical affairs" insights, driving targeted HCP engagement and operational efficiency. 

How AI-Powered Precision Is Reshaping Medical Affairs 

In today’s Pharma Pulse, the ACIP votes to end the decades-long universal hepatitis B birth dose recommendation; meanwhile, former FDA commissioners warn that new vaccine policies are compromising the long-standing regulatory framework and jeopardizing public health security.

Pharma Pulse: ACIP Ends Universal Hep B Birth Dose 

The entrepreneur urges the Trump administration to eliminate costly FDA generic drug fees, part of a broader push to scale domestic production, address shortages, and challenge PBM-driven pricing models.

Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion

In the final part of his Pharma Commerce video interview, Ed Schoonveld, value and access advisor for Schoonveld Advisory and author of The Price of Global Health, previews his December column, exploring US price-referencing guidance, its impact on innovation, and whether this marks the beginning of broader pricing controls.

What MFN Pricing Means for Future Drug Development

In today’s Pharma Pulse, Dr. Tracy Beth Høeg is named acting CDER director amidst high leadership turnover, promising modernization and transparency. 

Pharma Pulse: New CDER Director Appointed, as Medicaid Shows Potential to Save Cancer Lives

The pharma distribution giant is scaling its third-party logistics network across Europe and the United States, adding cryogenic capacity, new facilities, and enhanced cold chain services, to support rising demand for specialty pharmaceuticals and global market access.

Cencora Accelerates Global 3PL Expansion With Major Investments in Cold Chain and Specialty Logistics

In the second part of his Pharma Commerce video interview, Ed Schoonveld, value and access advisor for Schoonveld Advisory and author of The Price of Global Health, notes that while non-transferability could hinder smaller biotechs partnering late with pharma, most alliances are already in place before vouchers become relevant.

News